A recommended scale for cognitive screening in clinical trials of Parkinson's disease
Identifieur interne : 000040 ( Main/Corpus ); précédent : 000039; suivant : 000041A recommended scale for cognitive screening in clinical trials of Parkinson's disease
Auteurs : Kelvin L. Chou ; Melissa M. Amick ; Jason Brandt ; Richard Camicioli ; Karen Frei ; Darren Gitelman ; Jennifer Goldman ; John Growdon ; Howard I. Hurtig ; Bonnie Levin ; Irene Litvan ; Laura Marsh ; Tanya Simuni ; Alexander I. Tröster ; Ergun Y. UcSource :
- Movement Disorders [ 0885-3185 ] ; 2010-11-15.
English descriptors
Abstract
Cognitive impairment is common in Parkinson's disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to make recommendations for a cognitive scale that could screen for dementia and mild cognitive impairment in clinical trials of PD where cognition is not the primary outcome. This Task Force conducted a systematic literature search for cognitive assessments previously used in a PD population. Scales were then evaluated for their appropriateness to screen for cognitive deficits in clinical trials, including brief administration time (<15 minutes), assessment of the major cognitive domains, and potential to detect subtle cognitive impairment in PD. Five scales of global cognition met the predetermined screening criteria and were considered for review. Based on the Task Force's evaluation criteria the Montreal Cognitive Assessment (MoCA), appeared to be the most suitable measure. This Task Force recommends consideration of the MoCA as a minimum cognitive screening measure in clinical trials of PD where cognitive performance is not the primary outcome measure. The MoCA still requires further study of its diagnostic utility in PD populations but appears to be the most appropriate measure among the currently available brief cognitive assessments. Widespread adoption of a single instrument such as the MoCA in clinical trials can improve comparability between research studies on PD. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23362
Links to Exploration step
ISTEX:40D88EA675753E232188B486DDBDA998C7C06B26Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A recommended scale for cognitive screening in clinical trials of Parkinson's disease</title><author><name sortKey="Chou, Kelvin L" sort="Chou, Kelvin L" uniqKey="Chou K" first="Kelvin L." last="Chou">Kelvin L. Chou</name><affiliation><mods:affiliation>Departments of Neurology and Neurosurgery, University of Michigan, Ann Arbor, Michigan, USA</mods:affiliation></affiliation></author><author><name sortKey="Amick, Melissa M" sort="Amick, Melissa M" uniqKey="Amick M" first="Melissa M." last="Amick">Melissa M. Amick</name><affiliation><mods:affiliation>VA Boston Healthcare System and Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts, USA</mods:affiliation></affiliation></author><author><name sortKey="Brandt, Jason" sort="Brandt, Jason" uniqKey="Brandt J" first="Jason" last="Brandt">Jason Brandt</name><affiliation><mods:affiliation>Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Camicioli, Richard" sort="Camicioli, Richard" uniqKey="Camicioli R" first="Richard" last="Camicioli">Richard Camicioli</name><affiliation><mods:affiliation>Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada</mods:affiliation></affiliation></author><author><name sortKey="Frei, Karen" sort="Frei, Karen" uniqKey="Frei K" first="Karen" last="Frei">Karen Frei</name><affiliation><mods:affiliation>The Parkinson's and Movement Disorders Institute, Fountain Valley, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Gitelman, Darren" sort="Gitelman, Darren" uniqKey="Gitelman D" first="Darren" last="Gitelman">Darren Gitelman</name><affiliation><mods:affiliation>Departments of Neurology and Radiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Goldman, Jennifer" sort="Goldman, Jennifer" uniqKey="Goldman J" first="Jennifer" last="Goldman">Jennifer Goldman</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Growdon, John" sort="Growdon, John" uniqKey="Growdon J" first="John" last="Growdon">John Growdon</name><affiliation><mods:affiliation>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA</mods:affiliation></affiliation></author><author><name sortKey="Hurtig, Howard I" sort="Hurtig, Howard I" uniqKey="Hurtig H" first="Howard I." last="Hurtig">Howard I. Hurtig</name><affiliation><mods:affiliation>Depratment of Neurology, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Levin, Bonnie" sort="Levin, Bonnie" uniqKey="Levin B" first="Bonnie" last="Levin">Bonnie Levin</name><affiliation><mods:affiliation>Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Litvan, Irene" sort="Litvan, Irene" uniqKey="Litvan I" first="Irene" last="Litvan">Irene Litvan</name><affiliation><mods:affiliation>Department of Neurology, University of Louisville School of Medicine, Louisville, Kentucky, USA</mods:affiliation></affiliation></author><author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><affiliation><mods:affiliation>Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Simuni, Tanya" sort="Simuni, Tanya" uniqKey="Simuni T" first="Tanya" last="Simuni">Tanya Simuni</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Troster, Alexander I" sort="Troster, Alexander I" uniqKey="Troster A" first="Alexander I." last="Tröster">Alexander I. Tröster</name><affiliation><mods:affiliation>Department of Neurology, University of North Carolina‐Chapel Hill, Chapel Hill, North Carolina, USA</mods:affiliation></affiliation></author><author><name sortKey="Uc, Ergun Y" sort="Uc, Ergun Y" uniqKey="Uc E" first="Ergun Y." last="Uc">Ergun Y. Uc</name><affiliation><mods:affiliation>Department of Neurology, University of Iowa, Iowa City, Iowa, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Veterans Affairs Medical Center, Iowa City, Iowa, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:40D88EA675753E232188B486DDBDA998C7C06B26</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23362</idno><idno type="url">https://api.istex.fr/document/40D88EA675753E232188B486DDBDA998C7C06B26/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000040</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A recommended scale for cognitive screening in clinical trials of Parkinson's disease</title><author><name sortKey="Chou, Kelvin L" sort="Chou, Kelvin L" uniqKey="Chou K" first="Kelvin L." last="Chou">Kelvin L. Chou</name><affiliation><mods:affiliation>Departments of Neurology and Neurosurgery, University of Michigan, Ann Arbor, Michigan, USA</mods:affiliation></affiliation></author><author><name sortKey="Amick, Melissa M" sort="Amick, Melissa M" uniqKey="Amick M" first="Melissa M." last="Amick">Melissa M. Amick</name><affiliation><mods:affiliation>VA Boston Healthcare System and Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts, USA</mods:affiliation></affiliation></author><author><name sortKey="Brandt, Jason" sort="Brandt, Jason" uniqKey="Brandt J" first="Jason" last="Brandt">Jason Brandt</name><affiliation><mods:affiliation>Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Camicioli, Richard" sort="Camicioli, Richard" uniqKey="Camicioli R" first="Richard" last="Camicioli">Richard Camicioli</name><affiliation><mods:affiliation>Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada</mods:affiliation></affiliation></author><author><name sortKey="Frei, Karen" sort="Frei, Karen" uniqKey="Frei K" first="Karen" last="Frei">Karen Frei</name><affiliation><mods:affiliation>The Parkinson's and Movement Disorders Institute, Fountain Valley, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Gitelman, Darren" sort="Gitelman, Darren" uniqKey="Gitelman D" first="Darren" last="Gitelman">Darren Gitelman</name><affiliation><mods:affiliation>Departments of Neurology and Radiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Goldman, Jennifer" sort="Goldman, Jennifer" uniqKey="Goldman J" first="Jennifer" last="Goldman">Jennifer Goldman</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Growdon, John" sort="Growdon, John" uniqKey="Growdon J" first="John" last="Growdon">John Growdon</name><affiliation><mods:affiliation>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA</mods:affiliation></affiliation></author><author><name sortKey="Hurtig, Howard I" sort="Hurtig, Howard I" uniqKey="Hurtig H" first="Howard I." last="Hurtig">Howard I. Hurtig</name><affiliation><mods:affiliation>Depratment of Neurology, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Levin, Bonnie" sort="Levin, Bonnie" uniqKey="Levin B" first="Bonnie" last="Levin">Bonnie Levin</name><affiliation><mods:affiliation>Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Litvan, Irene" sort="Litvan, Irene" uniqKey="Litvan I" first="Irene" last="Litvan">Irene Litvan</name><affiliation><mods:affiliation>Department of Neurology, University of Louisville School of Medicine, Louisville, Kentucky, USA</mods:affiliation></affiliation></author><author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><affiliation><mods:affiliation>Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Simuni, Tanya" sort="Simuni, Tanya" uniqKey="Simuni T" first="Tanya" last="Simuni">Tanya Simuni</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Troster, Alexander I" sort="Troster, Alexander I" uniqKey="Troster A" first="Alexander I." last="Tröster">Alexander I. Tröster</name><affiliation><mods:affiliation>Department of Neurology, University of North Carolina‐Chapel Hill, Chapel Hill, North Carolina, USA</mods:affiliation></affiliation></author><author><name sortKey="Uc, Ergun Y" sort="Uc, Ergun Y" uniqKey="Uc E" first="Ergun Y." last="Uc">Ergun Y. Uc</name><affiliation><mods:affiliation>Department of Neurology, University of Iowa, Iowa City, Iowa, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Veterans Affairs Medical Center, Iowa City, Iowa, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-11-15">2010-11-15</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">15</biblScope><biblScope unit="page" from="2501">2501</biblScope><biblScope unit="page" to="2507">2507</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">40D88EA675753E232188B486DDBDA998C7C06B26</idno><idno type="DOI">10.1002/mds.23362</idno><idno type="ArticleID">MDS23362</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>cognitive impairment</term><term>cognitive screening</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cognitive impairment is common in Parkinson's disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to make recommendations for a cognitive scale that could screen for dementia and mild cognitive impairment in clinical trials of PD where cognition is not the primary outcome. This Task Force conducted a systematic literature search for cognitive assessments previously used in a PD population. Scales were then evaluated for their appropriateness to screen for cognitive deficits in clinical trials, including brief administration time (<15 minutes), assessment of the major cognitive domains, and potential to detect subtle cognitive impairment in PD. Five scales of global cognition met the predetermined screening criteria and were considered for review. Based on the Task Force's evaluation criteria the Montreal Cognitive Assessment (MoCA), appeared to be the most suitable measure. This Task Force recommends consideration of the MoCA as a minimum cognitive screening measure in clinical trials of PD where cognitive performance is not the primary outcome measure. The MoCA still requires further study of its diagnostic utility in PD populations but appears to be the most appropriate measure among the currently available brief cognitive assessments. Widespread adoption of a single instrument such as the MoCA in clinical trials can improve comparability between research studies on PD. © 2010 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Kelvin L. Chou MD</name><affiliations><json:string>Departments of Neurology and Neurosurgery, University of Michigan, Ann Arbor, Michigan, USA</json:string></affiliations></json:item><json:item><name>Melissa M. Amick PhD</name><affiliations><json:string>VA Boston Healthcare System and Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts, USA</json:string></affiliations></json:item><json:item><name>Jason Brandt PhD</name><affiliations><json:string>Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</json:string></affiliations></json:item><json:item><name>Richard Camicioli MD</name><affiliations><json:string>Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada</json:string></affiliations></json:item><json:item><name>Karen Frei MD</name><affiliations><json:string>The Parkinson's and Movement Disorders Institute, Fountain Valley, California, USA</json:string></affiliations></json:item><json:item><name>Darren Gitelman MD</name><affiliations><json:string>Departments of Neurology and Radiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA</json:string></affiliations></json:item><json:item><name>Jennifer Goldman MD</name><affiliations><json:string>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</json:string></affiliations></json:item><json:item><name>John Growdon MD</name><affiliations><json:string>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA</json:string></affiliations></json:item><json:item><name>Howard I. Hurtig MD</name><affiliations><json:string>Depratment of Neurology, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA</json:string></affiliations></json:item><json:item><name>Bonnie Levin PhD</name><affiliations><json:string>Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida, USA</json:string></affiliations></json:item><json:item><name>Irene Litvan MD</name><affiliations><json:string>Department of Neurology, University of Louisville School of Medicine, Louisville, Kentucky, USA</json:string></affiliations></json:item><json:item><name>Laura Marsh MD</name><affiliations><json:string>Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas, USA</json:string></affiliations></json:item><json:item><name>Tanya Simuni MD</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Center and Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA</json:string></affiliations></json:item><json:item><name>Alexander I. Tröster PhD</name><affiliations><json:string>Department of Neurology, University of North Carolina‐Chapel Hill, Chapel Hill, North Carolina, USA</json:string></affiliations></json:item><json:item><name>Ergun Y. Uc MD</name><affiliations><json:string>Department of Neurology, University of Iowa, Iowa City, Iowa, USA</json:string><json:string>Veterans Affairs Medical Center, Iowa City, Iowa, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>cognitive impairment</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>cognitive screening</value></json:item></subject><articleId><json:string>MDS23362</json:string></articleId><language><json:string>eng</json:string></language><abstract>Cognitive impairment is common in Parkinson's disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to make recommendations for a cognitive scale that could screen for dementia and mild cognitive impairment in clinical trials of PD where cognition is not the primary outcome. This Task Force conducted a systematic literature search for cognitive assessments previously used in a PD population. Scales were then evaluated for their appropriateness to screen for cognitive deficits in clinical trials, including brief administration time (>15 minutes), assessment of the major cognitive domains, and potential to detect subtle cognitive impairment in PD. Five scales of global cognition met the predetermined screening criteria and were considered for review. Based on the Task Force's evaluation criteria the Montreal Cognitive Assessment (MoCA), appeared to be the most suitable measure. This Task Force recommends consideration of the MoCA as a minimum cognitive screening measure in clinical trials of PD where cognitive performance is not the primary outcome measure. The MoCA still requires further study of its diagnostic utility in PD populations but appears to be the most appropriate measure among the currently available brief cognitive assessments. Widespread adoption of a single instrument such as the MoCA in clinical trials can improve comparability between research studies on PD. © 2010 Movement Disorder Society</abstract><qualityIndicators><score>7.708</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>3</keywordCount><abstractCharCount>1614</abstractCharCount><pdfWordCount>4816</pdfWordCount><pdfCharCount>31432</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>241</abstractWordCount></qualityIndicators><title>A recommended scale for cognitive screening in clinical trials of Parkinson's disease</title><corporate><json:item><name>on behalf of the Parkinson Study Group Cognitive/Psychiatric Working Group</name></json:item></corporate><genre><json:string>editorial</json:string></genre><host><volume>25</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>7</total><last>2507</last><first>2501</first></pages><issn><json:string>0885-3185</json:string></issn><issue>15</issue><subject><json:item><value>Viewpoint</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/mds.23362</json:string></doi><id>40D88EA675753E232188B486DDBDA998C7C06B26</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/40D88EA675753E232188B486DDBDA998C7C06B26/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/40D88EA675753E232188B486DDBDA998C7C06B26/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/40D88EA675753E232188B486DDBDA998C7C06B26/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">A recommended scale for cognitive screening in clinical trials of Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2010</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: The authors report no disclosures or conflict of interest concerning the research related to the manuscript.</note><note type="content">*Members of the “Parkinson Study Group Cognitive/Psychiatric Working Group” are listed as an Appendix.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">A recommended scale for cognitive screening in clinical trials of Parkinson's disease</title><author><orgName>on behalf of the Parkinson Study Group Cognitive/Psychiatric Working Group</orgName></author><author><persName><forename type="first">Kelvin L.</forename><surname>Chou</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: University of Michigan Medical School, 1500 E. Medical Center Drive, SPC 5316, Ann Arbor, MI 48109‐5316</p></note><affiliation>Departments of Neurology and Neurosurgery, University of Michigan, Ann Arbor, Michigan, USA</affiliation></author><author><persName><forename type="first">Melissa M.</forename><surname>Amick</surname></persName><roleName type="degree">PhD</roleName><affiliation>VA Boston Healthcare System and Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts, USA</affiliation></author><author><persName><forename type="first">Jason</forename><surname>Brandt</surname></persName><roleName type="degree">PhD</roleName><affiliation>Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</affiliation></author><author><persName><forename type="first">Richard</forename><surname>Camicioli</surname></persName><roleName type="degree">MD</roleName><affiliation>Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada</affiliation></author><author><persName><forename type="first">Karen</forename><surname>Frei</surname></persName><roleName type="degree">MD</roleName><affiliation>The Parkinson's and Movement Disorders Institute, Fountain Valley, California, USA</affiliation></author><author><persName><forename type="first">Darren</forename><surname>Gitelman</surname></persName><roleName type="degree">MD</roleName><affiliation>Departments of Neurology and Radiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA</affiliation></author><author><persName><forename type="first">Jennifer</forename><surname>Goldman</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation></author><author><persName><forename type="first">John</forename><surname>Growdon</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA</affiliation></author><author><persName><forename type="first">Howard I.</forename><surname>Hurtig</surname></persName><roleName type="degree">MD</roleName><affiliation>Depratment of Neurology, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA</affiliation></author><author><persName><forename type="first">Bonnie</forename><surname>Levin</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida, USA</affiliation></author><author><persName><forename type="first">Irene</forename><surname>Litvan</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University of Louisville School of Medicine, Louisville, Kentucky, USA</affiliation></author><author><persName><forename type="first">Laura</forename><surname>Marsh</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas, USA</affiliation></author><author><persName><forename type="first">Tanya</forename><surname>Simuni</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA</affiliation></author><author><persName><forename type="first">Alexander I.</forename><surname>Tröster</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Neurology, University of North Carolina‐Chapel Hill, Chapel Hill, North Carolina, USA</affiliation></author><author><persName><forename type="first">Ergun Y.</forename><surname>Uc</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University of Iowa, Iowa City, Iowa, USA</affiliation><affiliation>Veterans Affairs Medical Center, Iowa City, Iowa, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-11-15"></date><biblScope unit="volume">25</biblScope><biblScope unit="issue">15</biblScope><biblScope unit="page" from="2501">2501</biblScope><biblScope unit="page" to="2507">2507</biblScope></imprint></monogr><idno type="istex">40D88EA675753E232188B486DDBDA998C7C06B26</idno><idno type="DOI">10.1002/mds.23362</idno><idno type="ArticleID">MDS23362</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Cognitive impairment is common in Parkinson's disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to make recommendations for a cognitive scale that could screen for dementia and mild cognitive impairment in clinical trials of PD where cognition is not the primary outcome. This Task Force conducted a systematic literature search for cognitive assessments previously used in a PD population. Scales were then evaluated for their appropriateness to screen for cognitive deficits in clinical trials, including brief administration time (<15 minutes), assessment of the major cognitive domains, and potential to detect subtle cognitive impairment in PD. Five scales of global cognition met the predetermined screening criteria and were considered for review. Based on the Task Force's evaluation criteria the Montreal Cognitive Assessment (MoCA), appeared to be the most suitable measure. This Task Force recommends consideration of the MoCA as a minimum cognitive screening measure in clinical trials of PD where cognitive performance is not the primary outcome measure. The MoCA still requires further study of its diagnostic utility in PD populations but appears to be the most appropriate measure among the currently available brief cognitive assessments. Widespread adoption of a single instrument such as the MoCA in clinical trials can improve comparability between research studies on PD. © 2010 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>cognitive impairment</term></item><item><term>cognitive screening</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Viewpoint</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2009-09-18">Received</change><change when="2010-06-28">Registration</change><change when="2010-11-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/40D88EA675753E232188B486DDBDA998C7C06B26/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="150"><doi origin="wiley" registered="yes">10.1002/mds.v25:15</doi><numberingGroup><numbering type="journalVolume" number="25">25</numbering><numbering type="journalIssue">15</numbering></numberingGroup><coverDate startDate="2010-11-15">15 November 2010</coverDate></publicationMeta><publicationMeta level="unit" type="editorial" position="40" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23362</doi><idGroup><id type="unit" value="MDS23362"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Viewpoint</title><title type="tocHeading1">Viewpoints</title></titleGroup><copyright ownership="thirdParty">Copyright © 2010 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2009-09-18"></event><event type="manuscriptRevised" date="2010-02-23"></event><event type="manuscriptAccepted" date="2010-06-28"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.1.9 mode:FullText" date="2013-01-24"></event><event type="publishedOnlineEarlyUnpaginated" date="2010-09-28"></event><event type="publishedOnlineFinalForm" date="2010-11-10"></event><event type="firstOnline" date="2010-09-28"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">2501</numbering><numbering type="pageLast">2507</numbering></numberingGroup><correspondenceTo>University of Michigan Medical School, 1500 E. Medical Center Drive, SPC 5316, Ann Arbor, MI 48109‐5316</correspondenceTo><objectNameGroup><objectName elementName="appendix">APPENDIX</objectName></objectNameGroup><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23362.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="33"></count><count type="wordTotal" number="5437"></count></countGroup><titleGroup><title type="main" xml:lang="en">A recommended scale for cognitive screening in clinical trials of Parkinson's disease<link href="#fn1"></link> <link href="#fn2"></link></title><title type="short" xml:lang="en">Cognitive Screening in PD Clinical Trials</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Kelvin L.</givenNames><familyName>Chou</familyName><degrees>MD</degrees></personName><contactDetails><email>klchou@med.umich.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Melissa M.</givenNames><familyName>Amick</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Jason</givenNames><familyName>Brandt</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Richard</givenNames><familyName>Camicioli</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Karen</givenNames><familyName>Frei</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Darren</givenNames><familyName>Gitelman</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Jennifer</givenNames><familyName>Goldman</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af8"><personName><givenNames>John</givenNames><familyName>Growdon</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af9"><personName><givenNames>Howard I.</givenNames><familyName>Hurtig</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af10"><personName><givenNames>Bonnie</givenNames><familyName>Levin</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af11"><personName><givenNames>Irene</givenNames><familyName>Litvan</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au12" creatorRole="author" affiliationRef="#af12"><personName><givenNames>Laura</givenNames><familyName>Marsh</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au13" creatorRole="author" affiliationRef="#af13"><personName><givenNames>Tanya</givenNames><familyName>Simuni</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au14" creatorRole="author" affiliationRef="#af14"><personName><givenNames>Alexander I.</givenNames><familyName>Tröster</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au15" creatorRole="author" affiliationRef="#af15 #af16"><personName><givenNames>Ergun Y.</givenNames><familyName>Uc</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au16" creatorRole="author"><groupName>on behalf of the Parkinson Study Group Cognitive/Psychiatric Working Group</groupName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Departments of Neurology and Neurosurgery, University of Michigan, Ann Arbor, Michigan, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>VA Boston Healthcare System and Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts, USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="CA" type="organization"><unparsedAffiliation>Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="US" type="organization"><unparsedAffiliation>The Parkinson's and Movement Disorders Institute, Fountain Valley, California, USA</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="US" type="organization"><unparsedAffiliation>Departments of Neurology and Radiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</unparsedAffiliation></affiliation><affiliation xml:id="af8" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA</unparsedAffiliation></affiliation><affiliation xml:id="af9" countryCode="US" type="organization"><unparsedAffiliation>Depratment of Neurology, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA</unparsedAffiliation></affiliation><affiliation xml:id="af10" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida, USA</unparsedAffiliation></affiliation><affiliation xml:id="af11" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Louisville School of Medicine, Louisville, Kentucky, USA</unparsedAffiliation></affiliation><affiliation xml:id="af12" countryCode="US" type="organization"><unparsedAffiliation>Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas, USA</unparsedAffiliation></affiliation><affiliation xml:id="af13" countryCode="US" type="organization"><unparsedAffiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA</unparsedAffiliation></affiliation><affiliation xml:id="af14" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of North Carolina‐Chapel Hill, Chapel Hill, North Carolina, USA</unparsedAffiliation></affiliation><affiliation xml:id="af15" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Iowa, Iowa City, Iowa, USA</unparsedAffiliation></affiliation><affiliation xml:id="af16" countryCode="US" type="organization"><unparsedAffiliation>Veterans Affairs Medical Center, Iowa City, Iowa, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">cognitive impairment</keyword><keyword xml:id="kwd3">cognitive screening</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Cognitive impairment is common in Parkinson's disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to make recommendations for a cognitive scale that could screen for dementia and mild cognitive impairment in clinical trials of PD where cognition is not the primary outcome. This Task Force conducted a systematic literature search for cognitive assessments previously used in a PD population. Scales were then evaluated for their appropriateness to screen for cognitive deficits in clinical trials, including brief administration time (<15 minutes), assessment of the major cognitive domains, and potential to detect subtle cognitive impairment in PD. Five scales of global cognition met the predetermined screening criteria and were considered for review. Based on the Task Force's evaluation criteria the Montreal Cognitive Assessment (MoCA), appeared to be the most suitable measure. This Task Force recommends consideration of the MoCA as a minimum cognitive screening measure in clinical trials of PD where cognitive performance is not the primary outcome measure. The MoCA still requires further study of its diagnostic utility in PD populations but appears to be the most appropriate measure among the currently available brief cognitive assessments. Widespread adoption of a single instrument such as the MoCA in clinical trials can improve comparability between research studies on PD. © 2010 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: The authors report no disclosures or conflict of interest concerning the research related to the manuscript.</p></note><note xml:id="fn2"><p>Members of the “Parkinson Study Group Cognitive/Psychiatric Working Group” are listed as an <link href="#app1">Appendix</link>.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>A recommended scale for cognitive screening in clinical trials of Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Cognitive Screening in PD Clinical Trials</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>A recommended scale for cognitive screening in clinical trials of Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Kelvin L.</namePart><namePart type="family">Chou</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Departments of Neurology and Neurosurgery, University of Michigan, Ann Arbor, Michigan, USA</affiliation><description>Correspondence: University of Michigan Medical School, 1500 E. Medical Center Drive, SPC 5316, Ann Arbor, MI 48109‐5316</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Melissa M.</namePart><namePart type="family">Amick</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>VA Boston Healthcare System and Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jason</namePart><namePart type="family">Brandt</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Richard</namePart><namePart type="family">Camicioli</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Karen</namePart><namePart type="family">Frei</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>The Parkinson's and Movement Disorders Institute, Fountain Valley, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Darren</namePart><namePart type="family">Gitelman</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Departments of Neurology and Radiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jennifer</namePart><namePart type="family">Goldman</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">John</namePart><namePart type="family">Growdon</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Howard I.</namePart><namePart type="family">Hurtig</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Depratment of Neurology, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Bonnie</namePart><namePart type="family">Levin</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Irene</namePart><namePart type="family">Litvan</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Louisville School of Medicine, Louisville, Kentucky, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Laura</namePart><namePart type="family">Marsh</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Tanya</namePart><namePart type="family">Simuni</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alexander I.</namePart><namePart type="family">Tröster</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Neurology, University of North Carolina‐Chapel Hill, Chapel Hill, North Carolina, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ergun Y.</namePart><namePart type="family">Uc</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Iowa, Iowa City, Iowa, USA</affiliation><affiliation>Veterans Affairs Medical Center, Iowa City, Iowa, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="corporate"><namePart>on behalf of the Parkinson Study Group Cognitive/Psychiatric Working Group</namePart><description>Departments of Neurology and Neurosurgery, University of Michigan, Ann Arbor, Michigan, USAVA Boston Healthcare System and Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts, USADepartments of Psychiatry and Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USADivision of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, CanadaThe Parkinson's and Movement Disorders Institute, Fountain Valley, California, USADepartments of Neurology and Radiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USADepartment of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USADepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USADepratment of Neurology, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USADepartment of Neurology, University of Miami Miller School of Medicine, Miami, Florida, USADepartment of Neurology, University of Louisville School of Medicine, Louisville, Kentucky, USADepartment of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas, USAParkinson's Disease and Movement Disorders Center and Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USADepartment of Neurology, University of North Carolina‐Chapel Hill, Chapel Hill, North Carolina, USADepartment of Neurology, University of Iowa, Iowa City, Iowa, USAVeterans Affairs Medical Center, Iowa City, Iowa, USA</description></name><typeOfResource>text</typeOfResource><genre type="editorial" displayLabel="editorial"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2010-11-15</dateIssued><dateCaptured encoding="w3cdtf">2009-09-18</dateCaptured><dateValid encoding="w3cdtf">2010-06-28</dateValid><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">1</extent><extent unit="references">33</extent><extent unit="words">5437</extent></physicalDescription><abstract lang="en">Cognitive impairment is common in Parkinson's disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to make recommendations for a cognitive scale that could screen for dementia and mild cognitive impairment in clinical trials of PD where cognition is not the primary outcome. This Task Force conducted a systematic literature search for cognitive assessments previously used in a PD population. Scales were then evaluated for their appropriateness to screen for cognitive deficits in clinical trials, including brief administration time (<15 minutes), assessment of the major cognitive domains, and potential to detect subtle cognitive impairment in PD. Five scales of global cognition met the predetermined screening criteria and were considered for review. Based on the Task Force's evaluation criteria the Montreal Cognitive Assessment (MoCA), appeared to be the most suitable measure. This Task Force recommends consideration of the MoCA as a minimum cognitive screening measure in clinical trials of PD where cognitive performance is not the primary outcome measure. The MoCA still requires further study of its diagnostic utility in PD populations but appears to be the most appropriate measure among the currently available brief cognitive assessments. Widespread adoption of a single instrument such as the MoCA in clinical trials can improve comparability between research studies on PD. © 2010 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: The authors report no disclosures or conflict of interest concerning the research related to the manuscript.</note><note type="content">*Members of the “Parkinson Study Group Cognitive/Psychiatric Working Group” are listed as an Appendix.</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>cognitive impairment</topic><topic>cognitive screening</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Viewpoint</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>15</number></detail><extent unit="pages"><start>2501</start><end>2507</end><total>7</total></extent></part></relatedItem><identifier type="istex">40D88EA675753E232188B486DDBDA998C7C06B26</identifier><identifier type="DOI">10.1002/mds.23362</identifier><identifier type="ArticleID">MDS23362</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2010 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000040 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000040 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:40D88EA675753E232188B486DDBDA998C7C06B26
|texte= A recommended scale for cognitive screening in clinical trials of Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |